Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyIC + PD-1 mAb in Advanced HCC
NCT03732547Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of polyinosine-polycytidylic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 5 years. Status: unknown.
02
Drugs
polyinosine-polycytidylic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03732547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732547.